Drugs / Dezocine
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 46 trials | ||||||
| Phase 4 | NCT05861063 | Feb → Dec 2023 | acneiform dermatitis | Xijing Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT06439368 | Jan 2023 → Dec 2024 | — | Yangtze River Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT03147066 | Sep → Oct 2017 | interstitial cystitis | Jianjun Yang | Completed | No outcome recorded |
| Phase 4 | NCT02673723 | Mar 2016 → Aug 2018 | — | The First Affiliated Hospital of Anhui Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02114463 | Mar 2014 → Aug 2016 | — | Guangzhou General Hospital of Guangzhou Military Command | Unknown | No outcome recorded |
| Phase 4 | NCT02094339 | Mar 2014 → Jun 2016 | — | Guangzhou General Hospital of Guangzhou Military Command | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07401641 | Jun 2025 → Jun 2026 overdue | oral cavity cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| — | NCT02768168 | May → Jul 2016 | — | General Hospital of Ningxia Medical University | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 4 | NCT05515822 Comparator | Oct 2022 → Apr 2024 | — | Qiang Fu | Unknown | No outcome recorded |
| Phase 4 | NCT03014713 Background | Sep 2016 → Dec 2017 | — | Weifeng Tu | Unknown | No outcome recorded |
| — | NCT06000137 Comparator | Feb 2022 → Jan 2023 | — | Eye & ENT Hospital of Fudan University | Completed | No outcome recorded |
| — | NCT04906317 Comparator | Dec 2020 → Dec 2023 | — | Sixth Affiliated Hospital, Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT03823846 Comparator | Nov 2017 → Aug 2020 | anaplastic cancer, neuropathy, painful | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT02289586 Background | Jul 2014 → Feb 2016 | — | Futian People's Hospital | Unknown | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dezocine | “flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg” NCT02094339 ↗13“flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg” NCT02114463 ↗ “dezocine is a kappa opioid antagonist related to mild respiratory depression” NCT02673723 ↗ |
| Known as | Dalgan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1685 ↗ |
| Known as | Dezocina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1685 ↗ |
| Known as | Docozine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1685 ↗ |
| Known as | Dozocine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1685 ↗ |
| Known as | WY-16,225 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1685 ↗ |
| Action | Activate | “Mu opioid receptor partial agonist” CHEMBL1685 ↗ |
| Action | Inhibit | “dezocine is a kappa opioid antagonist” NCT02673723 ↗1“Kappa opioid receptor antagonist” CHEMBL1685 ↗ |
| Modality | Other / unclassified | “dezocine is a kappa opioid antagonist” NCT02673723 ↗ |
| Route | Intravenous | “An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine” NCT02094339 ↗ |
| Target | OPRK1 | “Kappa opioid receptor antagonist” CHEMBL1685 ↗ |
| Target | OPRM1 | “Mu opioid receptor partial agonist” CHEMBL1685 ↗ |